Genedx Holdings Stock Earnings Reports

Key takeaways for investors:

- Strong demand but stepped-back revenue: Q1 test result volume grew 34% YoY (27,488 tests) and exome/genome revenue was up 27%, demonstrating robust market demand. However, total Q1 revenue ($102.3M) was approximately $12M below internal expectations, prompting a business review and guidance reset. Blended average reimbursement rate (ARR) in Q1 was ~ $3,300.

- Drivers of the shortfall: Management attributes the revenue miss mainly to (1) a lower-than-expected blended ARR driven by product mix shifts within the exome/genome portfolio (not contractual price changes or broad coverage deterioration) and (2) softer-than-expected performance/timing in non-core lines (Fabric and biopharma/data). Fabric also incurred a non-cash impairment (~$31.3M).

- Updated guidance and financial priorities: Full-year 2026 revenue guidance was lowered to $475M–$490M (down ~12% at the midpoint). Management expects exome/genome volume growth of at least 30% (~126,400 tests), exome/genome revenue growth of at least 20%, adjusted gross margin around 70%, and adjusted profitability for the full year (with Q2 adjusted net loss of ~ $5M and a return to adjusted profitability in Q3). Q2 revenue guide is $110M–$112M.

- Cost and operational actions: Management has cut/realigned ~$25M of planned OpEx (slowing hires, marketing timing, some R&D and G&A) to prioritize three levers: growing utilization of exome/genome, optimizing unit economics (ARR and COGS), and delivering leading products at scale (including AI/automation to reduce COGS).

- Product and commercial dynamics: Genome mix rose faster than expected (genome ~40% of outpatient volume in Q1; ~45% including NICU), contributing to lower blended ARR because exome currently has broader payer coverage and higher ARR. Management introduced a Reflex product to manage transition and improve unit economics. They continue to invest in payer coverage, revenue cycle optimization, and international expansion for Fabric’s interpretation-as-a-service. Biopharma/data remains strategic but has longer sales cycles and is now treated as upside to guidance.

- Strategic outlook: Management reiterates conviction in long-term market opportunity and competitive moat (large dataset, GeneDx Infinity, expert team, rapid turnaround), expects ARR and genome economics to improve over time as coverage expands and revenue-cycle improvements are implemented, and positions the company to pursue profitable growth into 2027 and beyond.